- Home
- Products
- Customized ADCs
- ITGAV+ITGB3
- Anti-ITGAV+ITGB3 (Etaracizumab)-SPDB-DM4 ADC
Anti-ITGAV+ITGB3 (Etaracizumab)-SPDB-DM4 ADC (CAT#: ADC-W-2127)
This ADC product is comprised of an anti-ITGAV+ITGB3 monoclonal antibody conjugated via a SPDB linker to DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM1 binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- ITGAV+ITGB3
- Alternative Names
- ITGAV+ITGB3
- Overview
- Integrins are integral cell-surface proteins composed of an alpha chain and a beta chain. They are known to participate in cell adhesion as well as cell-surface mediated signalling. Integrins are heterodimeric integral membrane proteins composed of an alpha chain and a beta chain. CD51 encodes integrin alpha chain V. The I-domain containing integrin alpha V undergoes post-translational cleavage to yield disulfide-linked heavy and light chains, that combine with multiple integrin beta chains to form different integrins. Alpha-V integrins have been implicated in many developmental processes and are therapeutic targets for inhibition of angiogenesis and osteoporosis.
- Overview
- Humanized Anti-ITGAV+ITGB3 IgG1 antibody, Etaracizumab
- Generic name
- Etaracizumab
- Host animal
- Mouse
- Name
- SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate)
- Description
- Disulfide Linkers, are extensively exploited as a chemically labile linkage. Since the release of disulfide-linked drugs requires a cytoplasmic thiol cofactor, such as glutathione (GSH). Disulfides maintain stable at physiological pH and only when ADCs are internalized inside cells, the cytosol provides reducing environment including intracellular enzyme protein disulfide isomerase, or similar enzymes, drugs can be released.
- Name
- DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine)
- Description
- Derived from Maytansinoid,a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. The eponymous natural cytotoxic agent maytansine is a 19-member lactam (ansa macrolide) structure originally isolated from the Ethiopian shrub Maytenus ovatus. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, which interfere the formation of microtubules and depolymerize already formed microtubules, inducing mitotic arrest in the intoxicated cells.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-ERBB2 (Trastuzumab-HC-Y180)-DBCO-MMAF ADC (CAT#: ADC-W-243)
- Anti-TNFRSF10B (Drozitumab)-SMCC-DM1 ADC (CAT#: ADC-W-1868)
- Anti-TPBG (clone H8)-AcBut-CalichDMH ADC (CAT#: ADC-W-197)
- Anti-CD70 (clone 2F2)-VC-AFP ADC (CAT#: ADC-W-084)
- Anti-CD19 (Taplitumomab paptox)-SPDB-DM4 ADC (CAT#: ADC-W-771)
- Anti-CD70 (Vorsetuzumab)-MC-MMAF ADC (CAT#: ADC-W-952)
- Anti-SDC1 (Indatuximab )-SPDB-DM4 ADC (CAT#: ADC-W-2511)
- Anti-CD4 (Keliximab)-MC-MMAF ADC (CAT#: ADC-W-868)
- Anti-ITGB3 (Tadocizumab)-SMCC-DM1 ADC (CAT#: ADC-W-2604)
- Anti-TNFRSF17 (clone 1E1)-SMCC-DM1 ADC (CAT#: ADC-W-124)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-2127. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
CAT# | Product Name | Linker | Payload |
ADC-W-2131 | Anti-ITGAV+ITGB3 (Etaracizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2126 | Anti-ITGAV+ITGB3 (Etaracizumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-2130 | Anti-ITGAV+ITGB3 (Etaracizumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-2129 | Anti-ITGAV+ITGB3 (Etaracizumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-2128 | Anti-ITGAV+ITGB3 (Etaracizumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
CAT# | Product Name | Linker | Payload |
ADC-W-095 | Anti-LAMP1 (clone chMAbl)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-2611 | Anti-MS4A1 (Rituximab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-469 | Anti-CA6 (clone huDS6)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-2599 | Anti-GPNMB (Glembatumumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-324 | Anti-CD19 (clone huB4)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
CAT# | Product Name | Linker | Payload |
ADC-W-2616 | Anti-MS4A1-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-324 | Anti-CD19 (clone huB4)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-516 | Anti-FOLR1 (M9346A)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-095 | Anti-LAMP1 (clone chMAbl)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-422 | Anti-ITGAV (clone MF-T)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.